Skip to Main Content

ABBREVIATIONS

Abbreviations

BFU: burst-forming units

BFU-E: BFU erythrocyte

CFU: colony-forming units

CFU-E: CFU erythrocyte

CFU-GEMM: CFU granulocyte, erythrocyte, monocyte and megakaryocyte

CFU-GM: CFU granulocyte and macrophage

CFU-Meg: CFU megakaryocyte

CH3B12: methylcobalamin

CH3H4PteGlu1: methyltetrahydrofolate

CSF: colony stimulating factor

dTMP: thymidylate

dUMP: deoxyuridylate

EPO: erythropoietin

ESA: erythropoiesis-stimulating agent

FIGLU: formiminoglutamic acid

FL: FLT3 (FMS tyr kinase 3) ligand

FMS3: FMS tyr kinase 3

G-CSF: granulocyte colony-stimulating factor

GM-CSF: granulocyte-macrophage colony-stimulating factor

GVHD: graft-versus-host disease

HAART: highly active antiretroviral therapy

HFE: high Fe, hemochromatosis protein

HIF: hypoxia-inducible factor

HIV: human immunodeficiency virus

IFN: interferon

IL: interleukin

LAK: lymphokine-activated killer cell

M-CSF: monocyte-/macrophage-stimulating factor

NK: natural killer

PBSC: peripheral blood stem cell

PteGlu: pteroylglutamic acid, folic acid

SAM: S-adenosylmethionine

SCF: stem cell factor

TcII: transcobalamin II

TRA: thrombopoietin receptor agonist

HEMATOPOIESIS

The finite life span of most mature blood cells requires their continuous replacement, a process termed hematopoiesis. New cell production must respond to basal needs and states of increased demand. Erythrocyte production can increase more than 20-fold in response to anemia or hypoxemia, leukocyte production increases dramatically in response to systemic infections, and platelet production can increase 10- to 20-fold when platelet consumption results in thrombocytopenia.

The regulation of blood cell production is complex. Hematopoietic stem cells are rare marrow cells that manifest self-renewal and lineage commitment, resulting in cells destined to differentiate into the 10 or more distinct blood cell lineages. For the most part, this process occurs in the marrow cavities of the skull, vertebral bodies, pelvis, and proximal long bones; it involves interactions among hematopoietic stem and progenitor cells and the cells and complex macromolecules of the marrow stroma and is influenced by a number of soluble and membrane-bound hematopoietic growth factors. Several hormones and cytokines have been identified and cloned that affect hematopoiesis, permitting their production in quantities sufficient for research and, in some cases, therapeutic use. Clinical applications range from the treatment of primary hematologic diseases (e.g., aplastic anemia, congenital neutropenia) to use as adjuncts in the treatment of severe infections and in the management of patients with kidney failure or those undergoing cancer chemotherapy or marrow transplantation.

Hematopoiesis also requires an adequate supply of minerals (e.g., iron, cobalt, and copper) and vitamins (e.g., folic acid, vitamin B12, pyridoxine, ascorbic acid, and riboflavin); deficiencies generally result in characteristic anemias or, less frequently, a general failure of hematopoiesis (Hoffbrand and Herbert, 1999). Therapeutic correction of a specific deficiency state depends on the accurate diagnosis of the anemic state and on knowledge about the correct dose, the use of these agents in appropriate combinations, and the expected response.

GROWTH FACTOR PHYSIOLOGY

Steady-state hematopoiesis encompasses the tightly regulated production of more than 400 billion blood cells each day. The hematopoietic organ also is unique in adult ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.